NCT01056822 - Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft

Interventions

DRUG

Continue with same dose of MMF as patient was taking before randomisation

DRUG

Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours

Trial Locations (19)

15006

Novartis Investigative Site, A Coruña

18014

Novartis Investigative Site, Granada

28040

Novartis Investigative Site, Madrid

28041

Novartis Investigative Site, Madrid

31080

Novartis Investigative Site, Pamplona

33006

Novartis Investigative Site, Oviedo

38320

Novartis Investigative Site, San Cristóbal de La Laguna

39008

Novartis Investigative Site, Santander

45004

Novartis Investigative Site, Toledo

46017

Novartis Investigative Site, Valencia

47011

Novartis Investigative Site, Valladolid

48903

Novartis Investigative Site, Barakaldo

50009

Novartis Investigative Site, Zaragoza

07014

Novartis Investigative Site, Palma de Mallorca

08003

Novartis Investigative Site, Barcelona

08025

Novartis Investigative Site, Barcelona

08036

Novartis Investigative Site, Barcelona

Unknown

Novartis Investigative Site, Madrid

03010

Novartis Investigative Site, Alicante